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Hirsutism is a common and distressing symptom frequently
encountered in women with polycystic ovary syndrome
(PCOS), who also show relative insulin resistance. The aim of
this trial, in which hirsutism was the primary end point, was
to compare the efficacy of the oral antihyperglycemic medi-
cation metformin with that of an established treatment, com-
bined ethinyl estradiol and cyproterone acetate. Patients (n 
52) were randomized to receive either metformin (500 mg,
three times daily) or Dianette (ethinyl estradiol, 35 g; cypro-
terone acetate, 2 mg) treatment for 12 months, with assess-
ments before treatment, at 6 months, and at 12 months. Both
objective and subjective methods of evaluating hirsutism
were used, and in addition, patient perceptions were exam-
ined. The results show that metformin is potentially an effec-
tive treatment for moderate to severe hirsutism in women
with PCOS. They also suggest that in some respects (Ferri-
man-Gallwey score and patient self-assessment), it is more
efficacious than the standard treatment (Dianette). The ob-
jective evaluation of hair diameter reduction showed that
both treatments were moderately effective at multiple ana-
tomical sites. Dianette treatment was responsible for pro-
found suppression of androgen activity, in contrast to
metformin, which induced negligible change. However, met-
formin did reduce markers of insulin resistance. The data
suggest that hirsutism may be effectively treated by reducing
hyperinsulinemia. (J Clin Endocrinol Metab 88: 4116–4123,
2003)
HIRSUTISM IS EXCESSIVE hair growth in a male pat-tern distribution in women. It is not only distressing
to patients, but also presents a challenging clinical manage-
ment dilemma. In approximately 90% of women with hir-
sutism, the underlying disorder is either polycystic ovary
syndrome (PCOS) with its intrinsic hyperandrogenism or is
idiopathic, related to increased tissue sensitivity to andro-
gens (1). In fact, a high proportion of patients with idiopathic
hirsutism demonstrate polycystic ovaries (2), suggesting that
these two forms may not be easily distinguished.
PCOS is a heterogeneous disorder characterized by
chronic anovulation, hyperandrogenism, and hyperinsulin-
emia secondary to reduced insulin sensitivity. The increased
secretion of ovarian androgens is considered to be due to
increased insulin stimulation of ovarian steroid-secreting
cells by insulin itself and also insulin-stimulated growth
factors, including IGF-I, and decreased IGF-binding protein
(IGFBP) activity (3). Hyperandrogenism commonly mani-
fests itself as hirsutism (60–83%), acne (11–43%) (4), sebor-
rhea, and alopecia.
Androgens have been shown to be at least partly respon-
sible for promoting the anagen phase (growth phase) of the
hair cycle, leading to larger hair follicles (5) and bringing
about a change from vellus to terminal hair status. In vitro
studies show that the active androgen is 5-dihydrotestos-
terone, produced locally by the action of 5-reductase en-
zyme on testosterone (1). The anagen phase has also been
shown to be influenced by the growth factor, IGF-I. IGF-I is
carried in the circulation, predominantly by specific IGFBPs,
but it is also produced locally by the dermal papilla, where
it acts on both the dermis and epidermis (6, 7). The activity
of these growth factors depends on a number of factors,
including local and circulating binding proteins, which, in
turn, are also influenced by the actions of insulin. Thus,
women with PCOS may demonstrate abnormalities in the
metabolism of both of the major factors responsible for hir-
sutism: androgens and insulin/growth factors.
Women with PCOS suffer from a high incidence of acne,
which has also been linked with raised serum androgen (8),
insulin (9), and IGF-I (10) concentrations in the circulation.
The use of oral antihyperglycemic medication (OAM), pre-
dominantly metformin and the thiazolidenediones, in the
treatment of women with PCOS, has been shown to improve
insulin sensitivity and ovarian function. Treatment with the
OAM metformin reduced circulating insulin, LH, andro-
stenedione, and testosterone concentrations in a number of
studies, and protracted treatment has resulted in improve-
ments in body mass index (BMI), menstrual cycle regulation,
spontaneous ovulation rates, and spontaneous and assisted
pregnancy rates (11–13). It has been hypothesized that by
reducing circulating insulin concentrations, leading to de-
creased free androgen concentrations, OAMs may amelio-
rate hirsutism. In fact, examination of the literature shows
that most, but not all, controlled studies achieved modest
reductions in circulating free androgens using metformin
(13). A recent study in lean women with PCOS showed
significant reductions of circulating testosterone, even
though they were only modestly elevated before treatment
(14). However, changes in insulin and possibly IGF metab-
olism justify further examination of this therapeutic ap-
proach, because, as described above, changes in the growth
Abbreviations: BMI, Body mass index; CL, confidence limits; CV,
coefficient of variation; DHEAS, dehydroepiandrosterone sulfate; FG,
Ferriman-Gallwey; HOMA-IR, homeostasis assessment for insulin re-
sistance; IGFBP, IGF-binding protein; OAM, oral antihyperglycemic
medication; PCOS, polycystic ovary syndrome.
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factor environment may also be important in the treatment
of hirsutism.
Some recent reports have addressed the use of OAMs in
hirsutism (15–20). However, in none of them was hirsutism
a primary outcome measure, and no objective measure of
hair growth was undertaken. There has been one very small
study reporting the effect of metformin on hirsutism as a
primary end-point measure and using an objective measure
of hair growth (21). The results suggested that metformin
may show benefit compared with placebo.
The aim of this trial, in which hirsutism is the primary end
point, was first to elucidate whether metformin does have an
effect on hirsutism in women with PCOS, and second to
compare its efficacy with an established treatment for hir-
sutism, combined ethinyl estradiol and cyproterone acetate.
In doing so we have used objective techniques, validated
subjective methods of assessment of hirsutism, and incor-
porated patient perception measures.
Subjects and Methods
Study population
Women with PCOS (n  52), whose primary complaint was hirsutism
[Ferriman-Gallwey (FG) score, 8] were recruited from the Reproduc-
tive Endocrinology clinic at the Royal Infirmary (Glasgow, UK). The
diagnosis of PCOS included at least two of the three following features:
oligomenorrhea/amenorrhea, polycystic ovaries on ultrasound (2), or
an elevated free androgen index. Exclusion criteria included contrain-
dications to either metformin or Dianette (including BMI 38) and use
of oral contraception or metformin within the previous 3 months. None
had thyroid dysfunction, hyperprolactinemia, diabetes mellitus, or late-
onset congenital adrenal hyperplasia. Women taking medication known
to affect gonadal or adrenal function, or carbohydrate or lipid metab-
olism were also excluded. Women were also advised to use barrier
contraception if randomized to metformin.
Informed consent was obtained from each woman, and the study was
conducted at the Royal Infirmary after obtaining approval from the
ethics committee of the North Glasgow Hospitals University National
Health Service Trust.
Study design
Treatments. Patients were block-randomized (n  10/block) in a 1:1 ratio
to receive either ethinyl estradiol (35 g) and cyproterone acetate (2 mg;
Dianette, Schering AG, Berlin, Germany) or metformin (Glucophage,
Merck, West Drayton, UK) for a 12-month treatment course. Random-
ization was by random number tables. The patient number treatment
codes were held by a third party and were allocated individually after
obtaining written consent. A list of codes was kept by a third party, and
patient names were checked after completion of the trial. Medication
was commenced 1 wk after obtaining written consent. Dianette was
administered in the recommended regimen (35 g ethinyl estradiol plus
2 mg cyproterone acetate, 21 d/month, followed by a 7-d pill-free pe-
riod). Metformin (metformin hydrochloride) was administered orally at
a dose of 500 mg, three times daily.
Assessment program. At baseline (T0), 6 months (T6), and 12 months (T12),
all patients underwent clinical and hormonal assessments. These in-
cluded anthropometric measurements of height, weight (BMI), waist/
hip ratio, blood pressure, and hirsutism using the FG score and hair
diameter measurements. These assessments were performed by the
same trained observer (L.H.). The sebum excretion rate was also assessed
at each time point, and a side-effect profile was performed at 2, 6, and
12 months. Assessment of patient perception was recorded at 0, 6, and
12 months for hirsutism and acne. Circulating concentrations of insulin,
glucose, testosterone, SHBG, androstenedione, dehydroepiandros-
terone sulfate (DHEAS), 17-hydroxyprogesterone, cholesterol, triglyc-
erides, low density lipoprotein cholesterol, high density lipoprotein
cholesterol, IGF-I, and IGFBP-3 were also determined in a fasting blood
sample taken at T0, T6, and T12.
Methods
BMI was calculated using the equation: weight (kilograms)/height
(meters)2. The data were subgrouped for analysis of the impact of
BMI on responses using the median value for the study population
(BMI  34).
Waist and hip circumferences were measured to the nearest centi-
meter with a soft tape according to WHO criteria.
Blood pressure measurements were performed manually using a
sphygmomanometer in a standard clinical method. The heart sound
Korotkoff 4 was taken to ascertain diastolic measurement. Where BMI
was raised, a large cuff was used.
Hirsutism was assessed clinically, using the modified FG method (22)
carried out by the same researcher (L.H.). A value greater than 8 was
considered hirsute. The FG score has been shown to be reproducible to
a level of three points (23).
Hair diameter values were obtained from samples of terminal hair
collected from the chin, abdomen, anterior midthigh, and forearm of
each patient using a stitch cutter blade (Swann-Morton) to cut flush with
the skin. Multiple hairs from each site were fixed on a microscope slide
with the hair base to one end. Diameters were determined using digital
image analysis software (Image Pro Plus, Media Cybernetics, Silver
Spring, MD), with the calipers set in a vertical frame, perpendicular to
the axis of the hair. The section measured was adjacent to the hair base,
thus representing most recent hair growth. One investigator (L.H.,
blinded to treatment group) made all hair diameter measurements, and
the method technical error (multiple measurements of the same hair)
was less than 1% at a mean diameter of 86 m. The variability of
hair diameter within any one site was determined to be 16%. Mean hair
diameters were calculated by averaging the values from each anatomical
site (where possible, six hairs were used to calculate the site average) and
calculating a mean of the site averages per case.
Forehead sebum excretion rate tests were performed following stan-
dard methods (24). This involved fixing blotting paper in contact with
the forehead for 90 min, after which, a chemical extraction of sebum with
diethyl ether was performed, and the dried sebum was weighed (ex-
pressed as milligrams per square meter per hour).
Analytes: assay methods
Hormone concentrations were assayed in patient-specific batches to
eliminate the effect of interassay drift. Testosterone was assessed using
the semiautomated Immulite technology (Diagnostic Products, Los An-
geles, CA), whereas SHBG, DHEAS, IGF-I, and IGFBP-3 were assessed
with the Immulite 2000 analyzer (Diagnostic Products). Androstenedi-
one and 17-hydroxyprogesterone were assayed using in-house RIAs
[intraassay coefficients of variation (CVs), both 12%].
Plasma glucose was measured using the glucose oxidase method
(Advia 1650 Chemistry System, Bayer, Leverkusen, Germany; intraassay
CV, 2%), and insulin was measured using a competitive RIA (in-house;
intraassay CV, 8%).
Homeostasis assessment for insulin resistance (HOMA-IR) was cal-
culated from the fasting concentrations of insulin and glucose using the
following formula: HOMA-IR  fasting serum insulin (U/ml)  fast-
ing plasma glucose (mmol/liter)/22.5.
Plasma total cholesterol, triglyceride, and high density lipoprotein
cholesterol measurements were performed using a modification of the
standard Lipid Research Clinics protocol (25) with the Bayer Advia 1650
Chemistry System (intraassay CV, 2%).
Questionnaires
Patients were asked to assess their own status of hirsutism and acne,
and the effects of treatment at T0, T6, and T12. This was estimated in a
quantitative manner, using a mark on a visual analog sliding scale. In
the same questionnaire, they were asked to assess change in hair quality
and their need for use of cosmesis (i.e. methods of hair removal) at T6
and T12, using Boolean operators.
A side-effect profile questionnaire was completed after 2 months (T2),
at T6, and at T12 to assess worsening of symptoms compared with
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baseline, using Boolean operators. Issues covered included reduced
appetite, nausea, vomiting diarrhea, headache, breast tenderness, and
depression.
Statistics
Changes in parameters over time were assessed using repeated mea-
sures ANOVA, and differences between groups were evaluated using
a nonparametric test (Mann-Whitney). Comparisons between two time
points within the same patient were effected using paired t tests. Pro-




The baseline characteristics of the two treatment groups
were similar. The mean age of the Dianette group was 31.7
yr [95% confidence limits (CL), 26.8–36.5 yr], and that of the
metformin group was 31.3 yr (CL, 27.9–34.7). Normal (non-
hirsute) values for the FG score are less than 8, so the degree
of hirsutism in both groups was considerable, with the Di-
anette group showing a mean value of 22.8 (CL, 19.7–26.0)
and the metformin group a mean of 20.3 (CL, 17.8–22.9;
group difference, P  0.24). The patients were generally
obese (mean BMI, 31.8 and 31.7 for Dianette and metformin,
respectively), and the proportions of patients in each group
with BMI greater than 29 were: Dianette, 20 of 26; and met-
formin, 14 of 26. Elevated fasting insulin concentrations in
the circulation were observed (laboratory upper limit of nor-
mal, 13.9; mean values of 19.0 and 15.8 for Dianette and
metformin, respectively; P  0.92), and the proportions pa-
tients showing elevated fasting insulin were: Dianette, 8 of
26; and metformin, 9 of 26. Fasting glucose concentrations
were within the normal range. The free androgen index (nor-
mal upper limit, 7.9) was elevated in both groups (mean
values: Dianette, 15.8; metformin, 14.1), and the proportions
of patients in each group with a free androgen index above
7.9 were: Dianette, 16 of 26 (62%); and metformin, 14 of 26
(54%). Acne was generally not a profound problem among
the groups.
Figure 1 shows the process of patients from recruitment
and randomization and through the 12-month treatment pro-
gram. There were more patients discontinuing Dianette (n 
10) than metformin (n  8, including three pregnancies) and
for a greater variety of reasons (no significant difference
between the groups).
Hirsutism
Figure 2 shows that the FG score was significantly reduced
after treatment in both groups, using repeated measures
ANOVA. The degree of reduction in FG score was signifi-
cantly greater (P  0.01, by Mann-Whitney test) in the met-
formin group (25%) compared with the Dianette group
(5%). Twelve months of treatment with metformin resulted
in five patients with severe hirsutism (FG score, 15 at T0)
achieving a FG score of less than 15 (i.e. moderate/mild
hirsutism) of a total of 22, whereas only one did so after
Dianette treatment (of 25; P  0.08, by 2 test).
The mean hair diameters were significantly reduced (P 
0.001, by repeated measures ANOVA) in both groups during
the treatment program (Fig. 3) and to a similar degree (Di-
anette, 17% reduction; metformin, 12%; difference between
groups, P  0.15). Table 1 shows changes in hair diameter
according to anatomical site. In fact, the changes in hair
diameter appeared to be dependent upon either anatomical
site and/or baseline hair diameter in both treatment groups.
It can be seen that hairs on the forearm were relatively fine
at T0 and underwent negligible change, whereaas hairs on
the chin and abdomen were relatively coarse at T0 and un-
derwent considerable change (both groups).
Patient self-assessments
Table 2 shows that patient self-assessment (visual analog
scale) of both hirsutism (Fig. 4) and acne underwent signif-
FIG. 1. Randomization and process of patients from
recruitment to completion of treatment after 12
months with Dianette or metformin. Lost TFU, Lost
to follow-up.
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icant reduction in both groups (by ANOVA). There was no
difference between the treatment groups at T0, but at T12 the
metformin patients scored their hirsutism significantly lower
than the Dianette group (by Mann-Whitney test, P  0.01).
Table 3 demonstrates changes in patient perception of
specific qualitative aspects of their hirsutism. More than half
of the patients in both treatment groups assessed their hair
quality to be finer after treatment, and there was no differ-
ence between the treatments in this parameter. Approxi-
mately half of the metformin group recorded that their hair
growth rate was reduced at T6. This proportion was signif-
icantly (P  0.05) greater than that in the Dianette group. Half
of the metformin-treated patients responded with a reduced
requirement for the use of cosmesis (T6 and T12). This pro-
portion was not significantly greater than the Dianette group
at either time point. The overall appearance as a description
specific to hirsutism was improved in more than 50% at both
T6 and T12 in the metformin group. This was a significantly
greater proportion than in the Dianette group at both time
points.
Acne and sebum excretion
The degree of acne in general was low (secondary outcome
measure), but both groups believed that acne improved sig-
nificantly (Table 2) by self-assessment. There was no differ-
ence between the treatment groups in the responses recorded
(P  0.36).
The sebum excretion rates underwent modest improve-
ment (P  0.05) during Dianette treatment, but no change
during metformin treatment [Dianette, from 0.14 g/m2h at
T0 to 0.08 at T12 (P  0.04); metformin, 0.15 g/m2h at T0
to 0.12 at T12 (P  0.18)].
Hormone changes
The effects of Dianette treatment on hormone profiles at 6
and 12 months were profound (Table 4), with reduced total
androgens in the circulation and an increase in the SHBG,
effectively reducing free androgen levels to values below the
normal range. Similar changes were recorded in circulating
17-hydroxyprogesterone and DHEAS. However, there was
no effect on glycemic parameters, and the BMI did not
change over the 12-month course of treatment. In contrast,
metformin treatment showed negligible effects on circulating
total androgens, SHBG, free androgen index, or 17-
hydroxyprogesterone, although a significant (P  0.02) in-
crease in circulating DHEAS was observed. However, met-
formin treatment resulted in a significant decrease in the
glucose/insulin ratio and the logHOMA-IR, suggesting
improved efficiency of utilization of glucose secondary to
improved insulin sensitivity. There was no change in the
circulating IGF-I, IGFBP-1, or IGFBP-3 during metformin
treatment.
Blood pressure and circulating lipid profiles during
metformin treatment
Table 4 shows that Dianette treatment was not associated
with changes in blood pressure, whereas the patients treated
with metformin showed a clinically insignificant increase in
diastolic blood pressure. There was no change in systolic
blood pressure in either treatment group. The circulating
lipid profiles were normal and showed nonsignificant im-
provements during treatment with metformin (Table 4).
Changes in hirsutism and metformin treatment
Metformin treatment was associated with changes in the
FG scores, BMI, and improved indexes of insulin action.
FIG. 2. FG score assessment of hirsutism through the program of
treatment with Dianette or metformin over 12 months. The broken
line represents the upper limit of normal values.
FIG. 3. Mean terminal hair diameter values through the program of
treatment with Dianette or metformin over 12 months.
TABLE 1. Changes in mean hair diameter according to
anatomical site during 12 months treatment with Dianette or
metformin
Dianette Metformin
T0 T12 % P T0 T12 % P
Chin (m) 115 102 11 0.06 103 91 12 0.09
Abdomen (m) 100 75 25 0.0004 93 72 22 0.002
Mid-thigh (m) 89 71 20 0.0001 67 62 8 0.10
Forearm (m) 63 58 8 0.03 53 52 2 0.38
Combined (m) 92 76 17 0.001 79 69 13 0.004
The data were compared using paired t test analyses.
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There was little correlation among these specific changes.
Those individuals who lost more than one BMI point (n  11)
showed no greater reduction in FG score (reduction of 3.8 FG
units) compared with those who lost less weight (n  7;
reduction of 6.6 FG units, P  0.13). Similar analyses with the
glucose/insulin ratio showed that those showing the greatest
improvement in the ratio reduced their FG scores to the same
degree as those showing a relatively inferior response (mean
FG reductions, 4.8 and 5.0, respectively).
The changes in FG score showed poor correlations with
changes in glucose/insulin ratio and logHOMA-IR value
(glucose/insulin, r2  0.01; change in HOMA-IR, r2  0.004),
indicating that changes in hirsutism were relatively inde-
pendent of changes in both measures of insulin sensitivity.
The correlation of change in FG score with change in BMI
(r2  0.17) was not significant (P  0.08).
The population median BMI was 34, and responses were
examined according to the two BMI subgroups (n  9 each)
lying to either side of this value. The data suggest that BMI
may be a relevant factor with respect to treatment efficacy as
the leaner subgroup showed a tendency (P  0.08) to greater
improvement in FG score (6.8 U; 95% CL, 3.3–10.3) than the
more obese subgroup (3.0 U; 95% CL, 0.2–6.2). The same
subgrouping revealed that the change in the free androgen
index was significantly greater (P  0.03) in the leaner
subgroup.
A similar examination of changes in FG score in relation
to hyperandrogenemia before treatment (free androgen in-
dex, 7.9) failed to establish any relationship, as both groups
showed similar FG scores at T0 and T12, with similar degrees
of benefit.
Side effects
Table 5 shows the results of side effect recordings by those
patients who continued on each treatment despite side ef-
fects. It shows that the side effect profiles of both treatments
were moderate, and there was little difference between the
treatment groups. Gastrointestinal problems (including re-
duced appetite) affected approximately half of the patients
on metformin in the first 6 months, contrasting with the
Dianette group. Headache and breast tenderness were fea-
tures in both treatment groups, but there was no difference
between them.
Discussion
The results of this prospective, randomized, controlled
study show that metformin is an effective treatment for mod-
erate to severe hirsutism in women with PCOS. The data also
suggest that in some respects (FG score and patient self-
assessment), it is more efficacious than the gold standard
treatment, combined estrogen and antiandrogen (cyprot-
erone acetate), Dianette. The objective evaluation of one com-
ponent of hirsutism, hair diameter, showed that both treat-
ments were effective in reducing mean diameters at multiple
anatomical sites. However, this reduction was modest in
both treatment groups.
To our knowledge, this is the first comparative, random-
ized, controlled trial of sufficient duration and patient num-
ber to address the issue of efficacy and acceptability of met-
formin, in the treatment of hirsutism in women with PCOS,
as a primary outcome measure. Furthermore, the use of an
objective measure of one aspect of hair growth is an impor-
tant addition to the assessment, as subjective evaluations
may be influenced by many factors.
Previous trials addressing the use of OAMs for the treat-
ment of hirsutism in women with PCOS were not unani-
mous, but four of them suggested that metformin treatment
would be efficacious if addressed directly. However, the
studies generally suffered from small patient number, pa-
tients who were only mild to moderately hirsute (assessed by
FG score), and short therapeutic duration, and only one
study employed an objective measure of hair analysis. In
none of the trials was treatment acceptability or assessment
of response explored.
Our trial indicates that the recorded improvement in hir-
sutism also equated with patient perception of improvement,
which was strongly in favor of metformin compared with
Dianette. The acceptability of metformin as a treatment for
hirsutism appeared to be high. In addition, although side-
effects were similar in the two treatment groups, there was
a trend toward increased compliance in the metformin
group, as evidenced by a lower side effect-motivated drop-
TABLE 2. Comparison of patient’s own quantitative self-assessments of hirsutism and acne through and at the end of 12-month
treatment with either Dianette or metformin
Dianette Metformin Mann-WhitneyU test
T0 T6 T12 ANOVA
(P)
T0 T6 T12 ANOVA
(P)
Rx Groups T12
Hirsutism 7.4 7.1 6.6 0.005 7.0 5.0 3.9 0.0001 0.01
Acne 2.0 1.2 1.0 0.002 3.4 2.9 1.9 0.005 0.36
FIG. 4. Self-assessment scores through the program of treatment
with Dianette or metformin over 12 months.
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out rate (excluding pregnancies). This is important, as high
patient compliance is essential for optimal treatment effect,
given the length of time of the hair biocycle.
Overall, the results present a counterintuitive profile in the
observations of a limited change in circulating total and free
androgens at the same time as considerable improvements in
hirsutism. Hirsutism is a result of end-organ sensitivity as
well as direct androgen stimulation, and this tissue sensi-
tivity is known to be controlled by factors other than andro-
gens, such as insulin and IGF-I activity. In our study met-
formin treatment showed significant improvement in the
glucose/insulin ratio and the logHOMA-IR, but it had neg-
ligible impact on circulating androgens. In contrast, Dianette
virtually eliminated free androgens from the circulation, but,
in fact, showed little effect on severe hirsutism, as has been
recorded previously (4). Taken together, these data suggest
that addressing insulin insensitivity may be a more effective
therapeutic approach to hirsutism in women with PCOS than
aggressive suppression of androgens in the form of antian-
drogen therapy. Thus, hirsutism and hyperandrogenism
may be related through a common underlying mechanism in
addition to a direct androgen stimulant-response etiology.
The activity of IGF-I is related to both absolute circulating
concentrations and those of its carrier proteins, such as
IGFBP-3, which effectively reduce IGF potency. Women with
PCOS may have raised circulating free IGF-I, mediated
mainly through reduced IGFBPs, suggesting increased
growth factor stimulation (26, 27). However, we did not
demonstrate any change in the circulating concentrations of
IGF-I, IGFBP-3, or IGFBP-1 after metformin treatment; thus,
we may hypothesize that the beneficial effect of metformin
is unlikely to be due to an effect on circulating growth factor
stimulation. Correspondingly, benefit may be due to a mech-
anism involving local growth factor action at the dermal
papillae. The inability of metformin to decrease serum IGF-I
concentrations has been reported previously (28, 29).
The failure of metformin to influence circulating SHBG
concentrations beyond placebo or control is another surpris-
ing observation that has been recorded previously (13). The
pretreatment values would be considered low and repre-
sentative of a cohort of obese women with PCOS. The failure
to significantly change these values with protracted treat-
ment may reflect the confounding effect of obesity in the
patient cohort and the complex nature of SHBG control
mechanisms. Body mass has a profound influence on SHBG
secretion. The weight loss during the program was modest,
and the patients remained generally obese. It may be that a
greater degree of weight loss is needed to effect a substantial
increase in SHBG, such that higher doses of metformin
should be used in obese women.
TABLE 3. Proportions (presented as %) of patients reporting changes in qualitative aspects of hirsutism after 6-month (T6) and
12-month (T12) treatment with Dianette or metformin
T6 (%) T12 (%)
Dianette Metformin P Dianette Metformin P
Finer hair quality 59 56 ns 65 61 ns
Reduced rate of hair growth 24 56 0.02 65 44 ns
Reduced need for cosmesis 18 50 0.08 25 50 ns
Overall improved appearance
(hirsutism)
6 55 0.002 25 61 0.002
ns, Not significant.
TABLE 4. Changes in mean circulating hormone concentrations and anthropomorphic features over 6 and 12 months of treatment with





T0 T6 T12 T0 T6 T12
Fasting insulin (mU/liter) 16.5 14.5 15.0 0.7 15.8 12.0 11.3 0.07
Glucose (mmol/liter) 5.0 4.8 4.8 0.3 5.4 5.2 5.3 0.5
logHOMA-IR 0.49 0.39 0.44 0.35 0.49 0.37 0.32 0.03
Glucose/insulin 0.40 0.50 0.40 0.2 0.45 0.55 0.68 0.004
Testosterone (nmol/liter) 3.52 2.38 2.68 0.006 3.19 3.34 2.82 0.39
SHBG (nmol/liter) 31.4 141.1 117.4 0.0001 30.4 29.6 28.8 0.90
FAI 15.5 2.0 3.2 0.0001 14.1 15.5 12.9 0.4
DHEAS (mol/liter) 7.2 4.8 4.4 0.0002 6.8 7.9 7.4 0.02
Androstenedione (ng/ml) 11.6 7.7 8.2 0.0001 11.6 11.5 10.4 0.3
17OH Progesterone (nmol/liter) 5.4 2.3 3.1 0.0008 4.2 5.2 5.8 0.2
BMI 31.8 31.1 31.3 0.15 31.7 30.3 30.1 0.001
WHR 0.81 0.81 0.81 0.69 0.85 0.84 0.85 0.59
BP: diastolic (mm Hg) 73.1 73.4 72.8 0.97 74.4 76.4 80.3 0.01
BP: systolic (mm Hg) 118.8 116.3 116.3 0.58 119.1 117.2 120.4 0.71
Cholesterol (total: mmol/liter) 4.90 5.05 4.75 0.35 4.98 4.87 4.79 0.32
Triglycerides (mmol/liter) 1.68 1.68 1.54 0.72 1.48 1.24 1.27 0.19
LDL Cholesterol (mmol/liter) 2.81 2.43 2.55 0.40 3.08 2.94 2.85 0.39
HDL Cholesterol (mmol/liter) 1.41 1.64 1.51 0.01 1.29 1.27 1.31 0.52
IGF-I (ng/ml) 267 250 250 0.90
IGFBP-1 (ng/ml) 21.6 32.2 25.9 0.30
IGFBP-3 (ng/ml) 6.6 6.5 6.4 0.50
FAI, Free androgen index; WHR, waist/hip ratio; BP, blood pressure.
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We observed poor correlations between reduction in FG
score and changes in BMI or measures of insulin sensitivity,
suggesting that neither of these changes is directly respon-
sible for improvement in FG score, further suggesting that
beneficial effects may be due to endocrine changes not yet
determined, such as the evolution of growth factor and bind-
ing protein complexes at the local tissue level, secondary to
induced changes in insulin sensitivity.
The degree of acne in our patient cohort was generally low,
and it is difficult to extract useful conclusions from the data,
as there was no absolute difference between the two treat-
ment groups for sebum excretion over the 12 months. This
is probably related to the fact that acne was not a primary
complaint in our study.
The examination of the impact of morbid obesity on the
responses to metformin therapy suggest that in such women
metformin at a dose of 500 mg, three times daily, may have
reduced efficacy compared with that in leaner women. A
similar observation was recorded with morbidly obese
women with PCOS in aspects of improving ovarian function,
weight reduction, and circulating lipids (30). This observa-
tion suggests that either morbidly obese women are refrac-
tory to metformin therapy or, quite simply, that the current
dose is insufficient.
Lifestyle change and weight loss have been shown to be
effective means of treating many of the abnormalities asso-
ciated with PCOS (31, 32), and hirsutism may respond to this
approach. Crave et al. (33) suggested that metformin may
confer no additional advantage over weight loss, which con-
trasts with the analyses presented above.
In summary, the results of this study open the prospect of
a realistic treatment for a large number of women with hir-
sutism and PCOS, and possibly also idiopathic hirsutism, a
large proportion of whom (90%) have polycystic ovaries
(2). The beneficial effects do not appear to be mediated by
suppression of circulating androgens, which makes it pos-
sible that hyperinsulinemia or related metabolic pathways
may be important determinants of end-organ responses at
the level of the hair follicle. Future work should address this
therapeutic approach through examining optimal doses of
OAMs, either alone or in combination with antiandrogen
treatment.
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